Editorial companion

What stands out

Merck CEO Rob Davis told CNBC he expects the company’s experimental cancer vaccine co-developed with Moderna to become faster to manufacture over time, a practical update on production rather than a new scientific claim. The comment matters because speed of manufacture affects how quickly doses can move from a lab batch to patients and to paying customers, and it signals that Merck is focused on operational scaling alongside clinical development. The CEO emphasized manufacturing efficiency as a pathway to broader deployment, not a change to the underlying clinical data.